BMO Capital initiated coverage of BrightSpring Health (BTSG) with an Outperform rating and $40 price target BMO Capital sees a long runway for BrightSpring to sign additional limited distribution drug contracts while also benefiting from more generic conversions, which coupled with opportunities on the Provider Services side, support the firm’s three-year 12%+ EBITDA growth outlook, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services, Inc.: Strong Growth Potential and Buy Rating Affirmed by BMO Capital
- BrightSpring Health price target raised to $39 from $33 at Wells Fargo
- BrightSpring Health price target raised to $40 from $32 at Morgan Stanley
- BrightSpring Health Services Shines in Q3 Earnings Call
- BrightSpring Health price target raised to $38 from $32 at Mizuho